Incident and recurrent urolithiasis

1 paper1 finding

Associations

1

SGLT2 inhibitors

downin humans1HR 0.51–0.69

1 study

SGLT2 inhibitors are associated with incident and recurrent urolithiasis in humans (HRs 0.51–0.69; rate ratios 0.58–0.82).
“vs. GLP-1 RA, SGLT2i were associated with lower incident and recurrent urolithiasis outcomes”
ReviewCompared with GLP-1 receptor agonists in adults receiving antidiabetic pharmacotherapy
Sodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review
Translational andrology and urologySep 23, 2026

More on SGLT2 inhibitors

Latest

1 in 12 months

Translational Andrology and UrologyOct 13

Sodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review

Systematic review of observational studiesSGLT2 inhibitors